Essentials of Pediatric Hematology/Oncology Nursing

A CORE CURRICULUM

FOURTH EDITION
Contents

Acknowledgments ........................................................................ xi

Contributors ............................................................................. xiii

Section 1. Pediatric Hematology/Oncology Nursing Practice

History and Philosophy of Pediatric Oncology Nursing ......................... 2
Mary C. Hooke and Marilyn J. Hockenberry

Standards of Pediatric Oncology Nursing .............................................. 5
Joan O’Hanlon Curry and Revonda B. Mosher

Association of Pediatric Hematology/Oncology Nurses ......................... 9
Melody Ann Watral

Section 2. Pediatric Cancers

Overview of Childhood Cancer ............................................................. 14
Christina Baggott

Epidemiology of Childhood Cancer ......................................................... 15
Kathy Ruccione

Leukemia ..................................................................................... 25
Kathy McCarthy

Non-Hodgkin Lymphoma ................................................................ 32
Meredith Lahl

Hodgkin Lymphoma ...................................................................... 39
Meredith Lahl

Central Nervous System Tumors ............................................................ 44
Melody Ann Watral

Neuroblastoma ............................................................................. 50
Linda D’Andrea

Osteosarcoma .............................................................................. 58
Judith Ann Holloway and Joan O’Hanlon Curry

Ewing Sarcoma of Bone and Soft Tissue and Peripheral Primitive Neuroectodermal Tumors ............. 63
Rebecca D’Amore and Joan O’Hanlon Curry

Tumors of the Kidney ..................................................................... 67
Mary Cogan

Rhabdomyosarcoma ...................................................................... 73
Julie McMahan

Retinoblastoma .............................................................................. 78
Maura Murphy Abbott

Rare Tumors of Childhood ................................................................. 82
Maura Murphy Abbott

Bibliography .................................................................................. 86
Section 3. Overview of Hematology

Origin of Blood Cells. ................................................................. 90
Christina Baggott

Anemia. ................................................................................ 92
Christina Baggott

Neutropenia. ............................................................................ 95
Christina Baggott

Thrombocytopenia. ....................................................................... 97
Christina Baggott

Bibliography. ............................................................................ 99

Section 4. Childhood Cancer Treatment

Diagnostic and Staging Procedures ......................................................... 102
Ijeoma Julie Eche

History of Chemotherapy ................................................................ 106
Christine Sullivan

Clinical Trials. ........................................................................... 109
Elizabeth A. Gilger

Chemotherapy ............................................................................ 111
Cailin Toomey

Guidelines for the Safe Handling of Chemotherapy............................................ 140
Susanne Brewster Conley

Administration of Vesicants. ............................................................... 142
Mary Lynn Rae and Linda Madsen

Surgery. ................................................................................ 147
Carol Rossetto

Radiation Therapy. ........................................................................ 151
Joy Hesselgrave and Christine Chordas

Hematopoietic Stem-Cell Transplantation ................................................... 160
Robbie Norville and Sharon Staton

Biologic Response Modifiers. .............................................................. 180
Colleen Hill Dansereau

Cell and Gene Therapy. .................................................................... 186
Robbie Norville

Complementary and Alternative Treatments.................................................. 193
Laura Freedman

Bibliography. ........................................................................... 196

Section 5. Side Effects of Treatment

Bone-Marrow Suppression ............................................................... 200
Nan Werther
# Contents

- Impairment of the Immune System ......................................................... 203
  *Lisa Morrissey*
- Central Nervous System Complications ..................................................... 207
  *Tara Kelly*
- Ototoxicity ............................................................................ 215
  *Kathryn Matson*
- Endocrine Abnormalities ..................................................................... 217
  *Rebecca A. Monroe*
- Cardiac and Pulmonary Complications ...................................................... 219
  *Barbara Cuccovia*
- Gastrointestinal Complications ............................................................ 221
  *Joan O’Hanlon Curry and Colleen Nixon*
- Renal and Bladder Complications .......................................................... 232
  *Maura Padula*
- Skin Changes .......................................................................... 234
  *Caroline Costello*
- Musculoskeletal Complications ............................................................ 237
  *Sameeya Ahmed-Winston*
- Nutritional Complications ................................................................ 239
  *Tonya L. Bauer*
- Growth and Developmental Complications .................................................. 241
  *Maritza Salazar-Abshire*
- Pain ................................................................................. 244
  *Eufemia Jacob*
- Oncologic Emergencies .................................................................. 252
  *Rita Secola and Debbie Reid*
- Bibliography........................................................................... 259

## Section 6. Supportive Care

- Psychological Preparation and Support for Painful Procedures ......................... 264
  *Catherine Fiona Macpherson*
- Sedation for Painful Procedures............................................................ 267
  *Catherine Fiona Macpherson*
- Central Venous Access Devices ............................................................ 269
  *Kathleen Adlard*
- Nutritional Support .................................................................... 275
  *Nancy E. Kline*
- Treatment of Infections .................................................................. 281
  *Pat Wills Bagnato*
Section 7. Psychosocial Issues

Development in Children with Cancer and Blood Disorders: Introduction
Mary C. Hooke

Development of Infants (Birth–1 Year)
Mary C. Hooke

Development of Toddlers (1–3 Years)
Mary C. Hooke

Development of Preschoolers (4–6 Years)
Mary C. Hooke

Development of School-Age Children (7–12 Years)
Linda Madsen

Development of Adolescents (13–17 Years)
Linda Madsen

Development of Young Adults (18–25 Years)
Mary C. Hooke and Linda Madsen

Care of Families
Katherine Patterson Kelly

Cross-Cultural Care and Competence
Stephanie Gil

Spirituality
Susan O’Connor-Von

School Reentry and Attendance
Kendal Jackson Temple

Professional Nurse-Patient Relationships
Terri Boyce

Bibliography

Section 8. Patient and Family Education

Teaching According to Developmental Level
Kristen Graham

Family Education
Sara Mosadegh

Critical Teaching-Learning Periods
Sara Mosadegh

The Pediatric Hematology/Oncology Nurse as Educator
Sara Mosadegh

Bibliography
Contents

Section 9. Care of the Terminally Ill Child and the Family

Children and Death .............................................................. 366
  Angela M. Ethier
Physical Care of the Terminally Ill Child ................................. 368
  Janice Nuuhiwa
Psychosocial Care of the Terminally Ill Child .......................... 374
  Janice Nuuhiwa
Bereavement ........................................................................ 377
  Rebecca A. Monroe
Professional’s Grief, Distress, and Bereavement ......................... 380
  Cynthia Stutzer
Moral Distress ..................................................................... 383
  Cynthia Stutzer
Ethical Dilemmas in Terminal Care ........................................... 385
  Kristin Stegenga
Legal Concerns in Terminal Care ............................................. 388
  Kristin Stegenga
Bibliography .......................................................................... 389

Section 10. Late Effects of Childhood Cancer

Definition and Overview ......................................................... 392
  Wendy Hobbie and Claire A. Carlson
Central Nervous System ....................................................... 405
  Joanne Quillen
Hypothalamic-Pituitary Axis .................................................. 407
  Deborah Diotallevi and Elaine Pottenger
Thyroid Function .................................................................. 411
  Deborah Diotallevi and Elaine Pottenger
Vision and Hearing ................................................................ 413
  Debra Eshelman-Kent
Head and Neck ..................................................................... 416
  Maureen M. Reilly and Claire A. Carlson
Cardiovascular System .......................................................... 419
  Joanne Quillen
Respiratory System ................................................................ 421
  Claire A. Carlson and Maureen M. Reilly
Gastrointestinal and Hepatic Systems ....................................... 423
  Claire A. Carlson and Maureen M. Reilly
Genitourinary System ............................................................ 427
  Debra Eshelman-Kent
Reproductive System: Testes .............................................................. 430
Sue Ogle and Wendy Hobbie

Reproductive System: Ovaries ............................................................. 432
Sue Ogle and Wendy Hobbie

Musculoskeletal System .................................................................. 434
Debra Eshelman-Kent

Hematopoietic System ................................................................... 437
Claire A. Carlson and Jill Brace O’Neill

Immune System ........................................................................ 438
Claire A. Carlson and Jill Brace O’Neill

Second Neoplasms ..................................................................... 440
Elizabeth Whittam

Psychosocial Effects: Personal and Emotional ................................. 443
Lisa Schwartz, Lauren Daniel, Matthew Hocking, and Branlyn DeRosa

Psychosocial Effects: Employment and Insurance ........................ 445
Lauren Daniel, Matthew Hocking, and Lisa Schwartz

Psychosocial Effects: Educational Issues ....................................... 448
Matthew Hocking, Branlyn DeRosa, Lauren Daniel, and Lisa Schwartz

Promoting Health After Childhood Cancer .................................... 450
Roseann Tucci

Bibliography ........................................................................... 451

Section 11. Hematology

Autoimmune Hemolytic Anemia .................................................. 460
Karyn Brundige

Sickle-Cell Disease ..................................................................... 463
Rosalind Bryant

Thalassemia ............................................................................. 468
Rosalind Bryant

Glucose-6-Phosphate Dehydrogenase Deficiency ........................... 472
Deborah Robinson

Hereditary Spherocytosis .............................................................. 474
Susanne Rosenberg

Bone-Marrow-Failure Syndromes ................................................ 476
Joan O’Brien Shea

Shwachman–Diamond Syndrome .................................................. 484
Teresa Conte

Chronic Neutropenia ................................................................. 486
Karyn Brundige
Contents

Immune Thrombocytopenic Purpura ....................................................... 492
Susanne Rosenberg
Evans Syndrome ....................................................................... 494
Karyn Brundige
Thrombosis and Thrombophilia ........................................................... 498
Kathy Hurney
Hemolytic-Uremic Syndrome ............................................................. 501
Leticia Valdiviez
Paroxysmal Nocturnal Hemoglobinuria ...................................................... 506
Colleen Nixon
Hemophilia ........................................................................... 510
Teresa Conte
Von Willebrand Disease ................................................................. 516
Nancy E. Kline
Bibliography........................................................................... 521
Index .................................................................................. 525
Bone-Marrow Suppression

Nan Werther

Bone-marrow suppression results from an insult to normal functioning bone marrow, whether from disease or induced by chemotherapy or radiation. Suppression of the marrow leads to a decline in the hematopoietic stem-cell line of red blood cells (RBCs), white blood cells, and platelets. After myelosuppressive therapy, bone-marrow suppression can be noted within 10 to 14 days, with its lowest point identified as the nadir. The timing of the recovery of blood counts is affected by the treatment the patient receives as well as by the patient’s history of previous therapies. During blood count recovery, the patient remains at risk for serious infection and bleeding. Administration of blood products and colony-stimulating factors (CSFs) (i.e., granulocyte colony-stimulating factor [GCSF], granulocyte–macrophage colony-stimulating factor [GMCSF], Epogen) provides protection and assists in the recovery of the blood counts for the patient.

Conditions Related to Bone-Marrow Suppression

Anemia

Definition

Anemia is a deficiency in the number of RBCs necessary for normal tissue and organ oxygenation due to hemolysis, replacement of bone marrow by malignant cells, myelosuppression induced by chemotherapy or radiation, viral suppression, or the effects of a chronic disease.

Clinical Presentation

The symptoms of anemia include fatigue; pale skin, lips, and nail beds; tachycardia; tachypnea; decreased energy; and headache.

No evidence-based guidelines currently exist for determining when to transfuse a pediatric patient with RBCs; therefore, it is important to understand that laboratory values guide clinical decisions, and it is necessary to base transfusions on patient needs (Agrawal, Hastings, & Feusner, 2010) (Table 5-1).

Treatment

All pediatric RBCs must be leukocyte depleted and irradiated. Dosing for pediatric patients is 10–15 ml/kg over 2–4 hours, completed within 4 hours. Volume is based on ml/kg of the patient’s body weight, with the standard being 10 ml/kg (Agrawal et al., 2010). The hemoglobin should increase by 2–3 g/dl. Adult dosing is 1–2 units over 2–4 hours, completed within 4 hours. Packed RBCs must be ABO compatible (Table 5-2), based on patients’ ABO typing (American Red Cross, 2013).

Stimulation of erythropoiesis with EPO-stimulating agents (ESAs) such as erythropoietin (Epogen) should be considered, particularly for patients whose cultural and religious beliefs prevent them from receiving transfusions. Patients and families need to understand that guidelines on the use of ESAs and their safety and effectiveness are limited and have not been established in pediatric patients with cancer. In adult patients, such hematopoietic CSFs have been shown to decrease the need for red-cell transfusions, as well as improve the quality of life, particularly in patients who experience fatigue related to anemia (Agrawal et al., 2010).

Thrombocytopenia

Definition

Thrombocytopenia is a deficiency in the number of platelets necessary for blood clotting caused by
myelosuppressive therapy, malignant cells in the bone marrow, increased consumption of platelets (i.e., disseminated intravascular coagulation), or fever.

**Clinical Presentation**

Thrombocytopenia presents with petechiae, increased bruising, epistaxis, mucosal bleeding, hematuria, hematochezia, neurological changes secondary to intracranial bleeding, and spontaneous bleeding if platelet count is lower than 5,000/mm$^3$.

**Laboratory Findings**

- Mild thrombocytopenia: platelet count of 75,000/mm$^3$ to 99,999/mm$^3$
- Moderate thrombocytopenia: platelet count of 50,000/mm$^3$ to 74,900/mm$^3$
- Moderately severe thrombocytopenia: platelet count of 20,000 to 49,900/mm$^3$
- Severe thrombocytopenia: platelet count of <20,000/mm$^3$

**Treatment**

Maintain platelet count of >10,000/mm$^3$ by administering single-donor, irradiated, cytomegalovirus-negative, leukocyte-depleted platelets. The advantages of providing single-donor platelets are (a) it decreases donor exposure by using platelets obtained by the apheresis technology, (b) it reduces the potential transfusion-transmitted infections, and (c) it decreases the incidence of alloimmunization (Slichter, 2007). The number of units of platelets ordered for a patient is based on the weight of the child and the desired post-transfusion platelet count. A dose of 1 unit per 10 kg of single-donor platelets should increase the platelet count by 50,000–100,000 platelets/mm$^3$ by 1 hour posttransfusion (Agrawal et al., 2010). Consider maintaining a platelet count of >50,000/mm$^3$ for patients with signs of bleeding, high fever, hyperleukocytosis, a rapid decrease in platelet count, or coagulation abnormalities and for those undergoing invasive procedures such as lumbar punctures, bone marrow aspirations and biopsies, surgeries, or endotracheal intubation. The administration of oprelvekin (Neumega, IL-11)—a thrombopoietic growth factor that stimulates proliferation and maturation of megakaryocytes in the bone marrow, resulting in an increased number of circulating platelets—is controversial. Its safety and efficacy have not been established in pediatric patients, particularly those younger than 12 years of age (Children’s Oncology Group [COG], 2009). Platelet transfusion guidelines are summarized in Table 5-3.

## Neutropenia

**Definition**

*Neutropenia* is a reduction in circulating neutrophils or white blood cells that is determined by the percentage of segmented neutrophils and band neutrophils that constitute the total white blood cell (WBC) count. Neutropenia is the most severe consequence of bone-marrow suppression. The risk of infection is determined by the absolute neutrophil count (ANC). ANC is calculated as total WBCs x neutrophils (i.e., % polys + % bands).

**Clinical Presentation**

Neutropenia can be asymptomatic; however, if a patient is anemic or thrombocytopenic, he or she frequently is also neutropenic. The symptoms associated with neutropenia include fever and infection (bacterial, fungal, viral).

**Severity of Neutropenia**

- Mild: ANC of 1,500–1,900/mm$^3$
- Moderate: ANC of 1,000–1,499/mm$^3$

---

**Table 5-2. ABO Compatibility**

<table>
<thead>
<tr>
<th>Patient with ABO Blood Type</th>
<th>Can Donate Red Cells to</th>
<th>Can Receive Red Cells from</th>
</tr>
</thead>
<tbody>
<tr>
<td>O+</td>
<td>O+, A+, B+, AB+</td>
<td>O+, O-</td>
</tr>
<tr>
<td>O-</td>
<td>All types</td>
<td>O-</td>
</tr>
<tr>
<td>A+</td>
<td>A+, B+</td>
<td>A+, A-, O+, O-</td>
</tr>
<tr>
<td>A-</td>
<td>A-, A+, AB-, AB+</td>
<td>A-, O-</td>
</tr>
<tr>
<td>B+</td>
<td>B+, AB+</td>
<td>B+, B-, O+, O-</td>
</tr>
<tr>
<td>B-</td>
<td>B-, B+, AB-, AB+</td>
<td>B-, O-</td>
</tr>
<tr>
<td>AB+</td>
<td>AB+</td>
<td>All types Universal recipient</td>
</tr>
<tr>
<td>AB-</td>
<td>AB-, AB+</td>
<td>AB-, A-, B-, O-</td>
</tr>
</tbody>
</table>